Morphogenetic protein 2 (BMP-2) is normally expressed in the embryo promoting the development of several organs. Aberrant expression of BMP-2 occurs in approximately 98% of lung carcinomas, however, its role in regulating tumor growth is poorly understood. We show that BMP-2 induces Id-1 expression in lung cancer cell lines through its activation of Smad-1/5, which is dependent on cell culture conditions. A549 cells in DMEM/5% FCS BMP-2 activated Smad-1/5 and caused a transient increase in proliferation. In serum-free medium, BMP-2 induced significantly less Smad-1/5 activation and Id-1 expression, and produced significant growth inhibition. The affect of BMP-2 on tumor growth in vivo was substantially more significant. Recombinant BMP-2 coinjected with A549 cells, into nude mice increased proliferation and produced an increase in Id-1 expression. Forced expression of BMP-2 in A549 cells significantly enhanced tumor growth in the lungs following intravenous injection but not of subcutaneous tumors. Tumors in the lung were found to have an activated Smad-1/5 and expressed Id-1. Subcutaneous tumors expressed less activated Smad-1/5 and Id-1 than that of controls. Human lung carcinomas were also found to express an activated Smad-1/5 and Id-1. We provide evidence that BMP-2 promotes tumor growth. This paper highlights that cell culture experiments may not reveal the full biological affects of BMP-2, and its activity varies depending of the local environment.
Introduction
BMP-2 was originally described because it induces the entire cascade of endochondral bone formation (Wozney et al., 1988) . The BMPs are evolutionary conserved proteins from insects to humans. BMP-2 and the highly homologous BMP-4, are required for normal embryonic development. BMP-2/4 function as morphogens required for the development of the lung (Weaver et al., 1999) , heart (Jiao et al., 2003) , digits (Dahn and Fallon, 2000; Han et al., 2003) , limbs (Pizette et al., 2001) , central nervous (Mizuseki et al., 2003) system, and epidermis (Andl et al., 2004) . During development, BMP-2/4 enhance cell proliferation, stimulate cell survival pathways, and induces self-renewal of stem cells (Ying et al., 2003) . BMP-2/4 regulate postnatal tissues, which include the differentiation of ovarian granulosa cells (Souza et al., 2002) and the migration of smooth muscle and endothelial cells (Cunningham et al., 1992; Willette et al., 1999; Langenfeld and Langenfeld, 2004) . BMPs mediate signaling by activating serine kinase receptors, which activate the Smad-1/5 transcription factor (Yamashita et al., 1996) .
BMP-2 is overexpressed in approximately 98% of lung carcinomas (Langenfeld et al., 2005) . Expression of the mature BMP-2 protein was found to be 17-fold higher than that of normal lung tissue, or benign lung tumors (Langenfeld et al., 2005) . There is increasing evidence suggesting that BMP-2 promotes tumorigenesis. BMP-2 increased the invasiveness of melanoma (Rothhammer et al., 2005) and lung cancer cell lines (Langenfeld et al., 2003) . Recombinant BMP-2 increased tumor growth of A549 cells in nude mice, while the BMP-2 antagonist, noggin, caused a 50% reduction in tumor growth (Langenfeld et al., 2003) . The affects of BMP-2 on the proliferation of cancer cells has been conflicting. Some in vitro studies have shown that BMP-2 inhibits the growth of cancer cell lines (Tada et al., 1998; Ghosh-Choudhury et al., 2000; Mathura et al., 2000) . BMP-2 inhibited the proliferation of the LNCap prostate carcinoma cell line in the presence of androgen, while in the absence of androgen, BMP-2 stimulated proliferation (Ide et al., 1997) . Expression of a dominant-negative BMP type II receptor in a breast cancer cell line decreased proliferation, suggesting that the BMPs may promote cell growth (Pouliot et al., 2003) . BMP-2 has also been shown to enhance angiogenesis in developing tumors (Langenfeld and Langenfeld, 2004) . Furthermore, high expression of BMP-2 mRNA in stage I non-small-cell lung carcinomas correlated with a worse prognosis (Beer et al., 2002) .
Id-1 has been shown to be an important direct target of Smad-1/5 in other cell systems. BMP-2/4 stimulate self-renewal of embryonic stem cells through a Smad-1/ 5-mediated activation of Id-1 (Ying et al., 2003) . BMP-2 has been shown to induce the expression of Id-1 in osteoblasts (Ogata et al., 1993) , endothelial cells (Langenfeld and Langenfeld, 2004) , and breast cancer cell lines (Clement et al., 2000) . Id-1 is deregulated in a variety of carcinomas and studies have suggested that Id-1 behaves as an oncogene (Norton, 2000) . Forced expression of Id-1 immortalized primary human normal keratinocytes (Alani et al., 1999) . Id-1 is a cell cycle regulator and has been shown to enhance proliferation of several different cancer cell lines (Ouyang et al., 2002) . Id-1 has been shown to stimulate the invasiveness of cancer cell lines and promote metastasis of breast cancer cells (Fong et al., 2003) . The role of BMP-2 in regulating Id-1 expression in cancer is poorly understood.
The purpose of this study was to assess whether BMP-2 promotes or suppresses tumor growth. We determined that BMP-2 induces Id-1 in lung cancer cell lines through its activation of Smad-1/5. Using Id-1 as an indicator of Smad-1/5 activation, we examined both in vitro and in vivo the effects of BMP-2 on cell growth of human lung cancer cell lines. In vitro, BMP-2 activation of Smad-1/5 was transient and varied depending on the cell culture conditions. BMP-2 had a more pronounced growth-promoting effect in vivo that correlated with an activated Smad-1/5. This paper provides evidence that BMP-2 is growth promoting in tumors, but its biological effects are dependent on the local environment.
Results

Effects of BMP-2 on proliferation
Since prior studies suggest that the effects of BMP-2 on proliferation may vary with cell culture conditions, we assessed its effects on the proliferation of A549 cells in serum-free medium (SFM) and medium containing serum (DMEM/5% FCS). BMP-2 decreased DNA synthesis of A549 cells by 50% when cultured in SFM (Figure 1a ). To assess whether BMP-2 was inducing apoptosis, active caspase 3 and JC-1 nuclear staining was assessed by FACS. BMP-2 did not induce apoptosis under these cell culture conditions (data not shown). A549 cells continuously cultured in DMEM/5% FCS, BMP-2 (10 ng/ml) caused an approximate 25% increase in proliferation when compared to controls (Figure 1b) . To determine the long-term effects of BMP-2 on proliferation cell counts were performed. A549 cells cultured in DMEM/5% FCS and treated with BMP-2 (10 ng/ml) showed no significant difference in cell numbers on days 2 and 4, suggesting that the effects of BMP-2 in vitro, are only transient (data not shown).
We next examined whether BMP-2 promotes proliferation of A549 cells in nude mice. A549 cells were coinjected with Affi-Blue agarose beads coated with BMP-2 or BSA subcutaneously into athymic nude mice. We previously reported that recombinant BMP-2 coinjected with A549 cells caused a 50% increase in tumors growth (Langenfeld et al., 2003) . The coinjection of A549 cells with the BMP-2 antagonist, noggin, decreased tumor growth by 50% (Langenfeld et al., 2003) . Affi-Blue agarose beads have been shown to effectively deliver exogenous BMP-2 in vivo (Vainio et al., 1993; Tucker et al., 1998; Langenfeld et al., 2003) . Proliferation was assessed by immunohistochemistry staining for expression of Ki-67. At 14-19 days following subcutaneous injection only a few A549 cells treated with BSA were proliferating (Figure 1c ). The coinjection of recombinant BMP-2 induced a 7.5-fold increase in the number of proliferating A549 cells (Figure 1d and e) . These studies suggest that BMP-2 stimulates the proliferation of cancer cells in vivo.
BMP-2 activates Smad-1/5 in DMEM/5% FCS but not in SFM BMP-2 is thought to act predominantly through the activation of its transcription factor Smad-1/5, however, it has been shown to mediate Smad-1/5 independent signaling (Nohe et al., 2002) . The ability of BMP-2 to phosphorylate Smad-1/5 was examined by Western blot analysis using an antibody, which specifically recognizes the phosphorylated form. BMP-2 induced the phosphorylation of Smad-1/5 in A549 cells continuously cultured in DMEM/5% FCS ( Figure 2a ). A549 cells cultured in SFM showed no appreciable increase in pSmad-1/5 after being treated with BMP-2 ( Figure 2a ). Similar findings were seen with the H1299 non-small-cell lung cancer cell line (data not reported). Total Smad-1/5 expression was equivalent in A549 cells treated with BMP-2 cultured in either DMEM/5% FCS or SFM ( Figure 2b ). We examined whether BMP-2 induced the translocation of Smad-1/5 into the nucleus. BMP-2 induced a transient nuclear accumulation of Smad-1/5 in A549 cells cultured in DMEM/5% FCS ( Figure 2d and g) but not SFM (Figure 2f and g). The peak increase in nuclear Smad-1/5 accumulation was 30 min after BMP-2 treatment which is consistent to that reported for other cell types (Xiao et al., 2001 ).
Id-1 induction is dependent on cell culture conditions BMP-2 has been shown to induce mitogenic signaling in osteoblasts, which includes the phosphorylation of extracellular signal-regulated kinase (Erk)-1/2 (Lou et al., 2000) and Id-1 expression (Ogata et al., 1993) . BMP-2 induced the phosphorylation of Erk-1/2 in A549 and H1299 cells ( Figure 3a and data not shown). In both A549 and H1229 cells cultured in DMEM/5% FCS BMP-2 induced the protein expression of Id-1 (Figure 3a and data not shown). BMP-2 induced significantly less Id-1 expression in cells cultured in SFM (Figure 3a and b). BMP-2 also caused a significantly greater increase in Id-1 m-RNA expression in both the A549 (Figure 3c ) and H71229 ( Figure 3d ) cells that were cultured in DMEM/5% FCS compared to cells cultured in SFM.
BMP-2 regulates Id-1 through Smad-1/5 We used short interfering RNA (siRNA) to further evaluate the role of Smad-1 in regulating Id-1 expression. A 50-70% knockdown of Smad-1 in A549 cells caused an approximately 40% decrease the amount of Id-1 m-RNA in comparison to scrambled controls ( Figure 4a ). We also inhibited Smad-1/5 expression by establishing stable transfections of Tob and Tob3SA in A549 cells. Tob is a specific antagonist of Smad-1/5 found in mammalian cells (Yoshida et al., 2000) . Since phosphorylation of Tob by Erk-1/2 inactivates wild-type Tob (Suzuki et al., 2002) , we stably transfected A549 cells with Tob3SA, which has had its Erk-1/2 phosphorylation sites removed (Suzuki et al., 2002) . We next examined whether inhibition of Smad-1/5 by Tob3SA would attenuate BMP-2-induced proliferation of A549 cells. BMP-2 produced an approximately 14% increase in the proliferation of vector control cells (Figure 4d ), while causing a 24% decrease in the proliferation of the A549 TobSA cells (Figure 4e ) that were cultured in DMEM/5% FCS. These data suggest that activation of Smad-1/5 inhibits BMP-2 growth suppressive affects.
BMP-2 enhances growth of A549 cells in mouse lungs
To further understand the role of BMP-2 in promoting tumor growth A549 cells were stably transfected with BMP-2 cDNA. These cells express higher levels of BMP-2 when compared to vector control (Langenfeld et al., 2003) . In vitro, we found that there was no difference in proliferation, Id-1 or pSmad-1/5 expression between A549/BMP-2 and A549/vector cells (data not shown). Therefore, forced expression of BMP-2 did not produce enhanced activation of Smad-1/5 signaling in A549/ BMP-2 cells in culture. We next asked whether BMP-2 would produce a more sustained response in nude mice. When A549/BMP-2 cells were injected subcutaneously into nude mice they formed tumors that were smaller cells than those of controls (Table 1) Id-1 and pSmad-1/5 expression in human NSCLC Id-1 has been shown to be expressed in several human tumors, however, its expression in lung carcinomas has not been reported. Although the mature BMP-2 protein is highly expressed in lung carcinomas, the activation of Smad-1/5 has not been studied, to our knowledge, in any human tumor. Semiquantitative PCR demonstrated 10 of 10 non-small-cell lung carcinomas expressed Id-1. Six of the 10 tumors expressed more Id-1 in comparison to normal lung tissue (data not shown). Immunofluorescent staining demonstrated that lung cancer cells express phosphorylated Smad-1/5 (Figure 7a ) and Id-1 (Figure 7b ).
Discussion
This study provides evidence that BMP-2 promotes the growth of tumors, which occurs in part by stimulating the proliferation of cancer cells. The effect of BMP-2 on the proliferation of our cell lines in vitro was only transient, suggesting it may not be a strong mitogen. However, the biological activity of BMP-2 may be substantially greater in vivo than that seen in vitro. This is supported by our mouse studies showing that BMP-2 significantly enhanced tumor growth. BMPs can induce the expression of antagonists that may limit the duration of activity in cell culture experiments (Kameda et al., 1999; Nifuji and Noda, 1999) . During development BMP-2/4 form a functional gradient, which can elicit different biological responses (Nellen et al., 1996; Myers et al., 2002; Sutherland et al., 2003) . The activity gradient of BMP-2/4 is determined by its concentration, as well as intracellular (Yoshida et al., 2000) and extracellular inhibitors (Paine-Saunders et al., 2002) . BMP-2 is secreted from the cell and then becomes attached to the extracellular matrix (Paine-Saunders et al., 2002) . This interaction with the extracellular matrix is essential for BMP-2-mediated responses (Suzawa et al., 1999) . The ability of BMP-2 to interact with the extracellular matrix may allow for a more sustained mitogenic response. This conclusion is supported by the in vitro experiments showing BMP-2 induced only a transient activation of Smad-1/5, while in nude mice there was a more sustained increase in pSmad-1/5 and Id-1. These data suggest that the activation of Smad-1/5 is essential for BMP-2 to promote tumor growth. Forced expression of BMP-2 in A549 cells enhanced tumor growth in the lungs following i.v. injection. The lung tumors were found to have an activated Smad-1/5, and expressed its target gene Id-1. The same cell line developed smaller tumors than control cells when injected subcutaneously into nude mice. These primary tumors expressed less pSmad-1/5 and Id-1 than controls. These data suggest that the site and how BMP-2 is delivered affects its ability to induce pSmad-1/5 and subsequent tumor growth. The application of recombinant BMP-2 directly on the tumors enhanced pSmad and Id-1 expression in subcutaneous tumors. This may be because BMP-2 delivered from Affi-Blue agarose beads can readily diffuse into surrounding tissue, delivering biologically active BMP-2 to the tumor. BMP-2 secreted from the cell may not diffuse as far in the subcutaneous tissue, allowing inhibition by natural antagonists (Paine-Saunders et al., 2002) . Human tumors rarely metastasize to the skin, suggesting the subcutaneous position is not the best environment for human tumors. Lung tissue may provide a better environment for BMP-2 to establish a more sustained response. This hypothesis is supported by the detection of activated Smad-1/5 and Id-1 in NSCLC. The ability of BMP-2 to induce Smad-1/5 activation in cell culture also correlated with cell growth and Id-1 expression.
Studies have shown that Smad-1/5 activity can be modified by signaling pathways other than the BMP receptors. Epidermal growth factor (EGF)-induced receptor tyrosine kinase activation suppresses BMP-2-induced differentiation of osteoblasts by interfering with Smad-1 activity (Nakayama et al., 2003) . Integrin activation of focal adhesion kinase (FAK) induces Ras and the downstream Erk in ostoeblasts. FAK activated Ras-Erk stimulates Smad-1 activity in response to BMP-2 in osteoblasts (Suzawa et al., 2002) . The Ras-Erk-signaling pathway is activated by serum. Therefore, BMP-2-induced activation of Smad-1/5 in cancer cells may require sustained Ras-Erk activity, which does not occur in SFM.
BMP-2 stimulation of tumor growth is most likely mediated through several mechanisms. The present study provides evidence supporting that BMP-2 promotes tumor growth by stimulating growth of the cancer cells. The large size of the tumors formed in the lungs by the A549/BMP-2 cells demonstrates significant cell growth. This amount of growth cannot be explained by an increased cell migration, and/or invasion. BMP-2 induced in lung cancer cells the expression Id-1 and pErk-1/2 both of which have been shown to promote cell growth. Several studies have suggested that Id-1 behaves as an oncogene regulating cell growth and metastasis (Ouyang et al., 2002; Fong et al., 2003; Lee et al., 2003) . Since BMP-2 is a direct regulator of Id-1 in normal cells, an important question is whether BMP-2 is an essential regulator of Id-1 expression in cancer. Many studies have shown that Erk-1/2 is a strong mitogen of cancer cells and its expression is transforming (Troppmair et al., 1994) . It is likely that BMP-2 may enhance tumor growth by a variety of mechanisms, which could include angiogenesis, cell growth, cell survival, induction of other cytokines, and perhaps regulation of stem cells.
This study highlights that in vitro cell culture experiments may not reveal the true biological significance of BMPs in cancer. We provide evidence supporting that BMP-2 promotes tumor growth in which Smad-1/5 activation is essential and is dependent on the local environment.
Materials and methods
Cell culture
The A549 and H1229 lung cancer cell lines (Langenfeld et al., 2003) were cultured in Dulbecco's Modified Eagle's medium (DMEM, Sigma Aldrich, St Louis, MO, USA) with 5% fetal bovine serum (FBS). Cells were carried continuously in DMEM/5% FCS prior to being treated with recombinant BMP-2. For serum starvation, cells were cultured in LHC-8 SFM (Biofluids, Rockville, MD, USA) for 4 h before recombinant BMP-2 (R & D systems) treatment.
Cloning and transfection of BMP-2
Full-length human BMP-2 cDNA was cloned into the pcDNA3.1 expression vector (Invitrogen) (Langenfeld et al., 2003) . A549 cells were cotransfected by electroporation lines with pCMV-EGFP vector (BD Biosciences, Palo Alto, CA, USA) and BMP-2/pcDNA3.1 plasmid (A549/BMP-2) (Langenfeld et al., 2003) . Control cells were cotransfected with the pcDNA3.1 and EGFP expression vectors (A549/BMP-2). Cells were selected with 50 mg/ml neomycin and GFP-expressing cells were sorted by FACS.
Western blot analysis
Total cellular protein was prepared using RIPA buffer and protein concentration was measured using the Bradford assay as described (Langenfeld et al., 2003) . Antibodies used were rabbit antiphospho Smad-1/5 (Upstate Biotechnology, Lake Placid, NY, USA), rabbit anti-Id-1 (Santa Cruz), mouse antipErk-1/2 (Promega, Madison, WI, USA), and actin (Sigma, St Louis, MO, USA).
Proliferation assay A549 cells were plated in duplicate at 2.0 Â 10 5 cells/well in sixwell tissue culture plates (Falcon, Franklin Lakes, NJ, USA) in 5% FCS/DMEM and allowed to adhere overnight. Cells were then cultured in 5% FCS/DMEM or SFM and treated with BMP-2 or vehicle control for 24 h. Cell were then incubated with 4 mCi/ml H 3 thymidine at 371C for 1 h. Cells were washed in cold PBS and then treated with 5% trichloroacetic acid. Cells were treated with 70% ethanol, lysed with 1% SDS/ 10 mM NaOH and incorporated H 3 thymidine measured in a scintillation counter (Langenfeld and Langenfeld, 2004 ).
Smad nuclear trans-localization A549 cells grown on glass cover slips were cultured in DMEM/ 5% FCS or SFM. A549 cells were treated with 10 ng/ml BMP-2, then fixed with 3.7% formaldehyde, permealized with 0.5% Triton X, and blocked with 1% BSA/PBS. Cells were incubated overnight with a 1:50 dilution of anti-Smad-1/5/8 antibody (Santa Cruz, CA, USA) at 41C. Alexa Fluor 488 antigoat IgG was used as the secondary antibody (Molecular Probes, Eugene, OR, USA). Negative controls included primary antibody preincubated with blocking peptide at a 10:1 ratio (Santa Cruz) and Alexa Fluor 488 IgG secondary antibody. A minimum of 100 cells were examined and the percent expressing Smad-1/5/8 in the nucleus determined (Langenfeld and Langenfeld, 2004) .
In vivo tumor growth A549 cells were coinjected subcutaneously into NCI athymic nude mice with recombinant BMP-2 or BSA. Recombinant protein was delivered to the tumors using Affi-Blue agarose beads as previously described (Langenfeld et al., 2003) . In brief, 25 mg of Affi-Blue agarose beads were coated with 20 ml of 100 mg/ml of BSA, or recombinant human BMP-2. The coated Affi-Blue agarose beads were coinjected with the 10 7 A549 cells subcutaneously into the flanks of nude mice. After 14-19 days, the mice were killed and the tumors frozen in liquid nitrogen. The experiments were performed three times.
A549/Vector and A549/BMP-2 cells ( 10 7 ) were injected subcutaneously into the flanks of NCI nude mice. The mice were euthanized after 3 weeks and tumor size determined (length Â depth Â width). The experiments were performed three times.
The A549/Vector and A549/BMP-2 cells (2 Â 10 6 ) were also injected into the tail veins of NCI nude mice. The presence of tumor growth in the lungs was examined after 3 months. The lungs were excised and the number of tumors counted. If tumors growth in the lungs was too numerous to count it was recorded as confluent with tumor. In all, 10 animals from each group were injected into the tail veins of the nude mice.
The mice studies were approved by the Robert Wood Johnson Medical School Institutional Animal Care and Use Committee.
Immunohistochemistry
Immunohistochemistry on mouse tumors were performed as previously described (Langenfeld et al., 2003) . Sections were cut stained for Ki-67 (1:100) (PharMingen, San Diego, CA, USA) overnight at 41C using the M.O.M. kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's protocol. Positive control included a mouse liver. Negative controls consisted of samples treated with secondary antibody alone.
Immunofluorescent imaging of pSmad-1/5 and Id-1 in tumors Human lung tumors and metastatic tumors to mouse lung were frozen in liquid nitrogen. Cut sections were treated with 1:1 solution of acetone/methanol, blocked with 1 Â PBS/1% BSA, and incubated with primary antibody overnight at 41C Primary antibodies were anti-pSmad-1/5 (Tamaki et al., 1998) (1:500 dilution) anti-Id (4 mg/ml) (Santa Cruz). To help identify tumor cells, tissues were costained with anticytokeratin antibody CAM 5.1 (BD Biosciences,San Jose, CA, USA). Goat IgG Alex Flour 488 or 568 were used for secondary antibodies. Negative controls included secondary antibody alone, which did not show any expression. Sections were analysed using immunofluorescent imaging. Five human NSCLC and three metastatic A549 tumors were analysed.
siRNA Synthetic short interfering RNA (siRNA) and transfection kit (siPORT) were purchased from Ambion (Austin, TX, USA). Cells (35 000) were transfected with 50 nM of siRNA using siPORT as per manufacturer's instructions. Scramble siRNA was used as a control. RNA was collected 48 h after transfection.
RNA extraction and semiquantitative PCR RNA was extracted using RNeasy kit as per manufacturer's instructions (Qiagen, Valencia, CA, USA). cDNA was generated using Advantage RT for PCR kit (BD BiosciencesClontech, Palo Alto, CA, USA). Real-time PCR was performed with the Lightcycler (Roche). SYBER Green was used to detect double-stranded DNA. The HotStart Taq Polymerase kit was used for the PCR mix with 20 mM of primers(Qiagen). Samples were denatured at 951C for 15 s, annealing 20 s, and extension 721C for 20 s for 35 cycles. DNA contamination was tested by PCR of RT samples. Negative control includes reagents, except cDNA. Expression is normalized to actin using the formula 2 DCT . Primers for Id-1 were 5 0 -TTA CGT GCT CTG TGG GTC TC-3 0 and 5 0 -CCC CCT AAA GTC TCT GGT GA-3 0 . Primers for Smad-1 were 5 0 -CTA CCC TCA CTC TCC CAC CA-3 0 and 5 0 -GCA CCA GTG TTT TGG TTC CT-3 0 .
Statistical analysis
To evaluate multiple groups, a one-way ANOVA, followed by Fisher LSD post hoc test was used to compare individual means. To compare two groups, a Student's t-test was used. Differences with P-values p0.05 were considered statistically significant.
